Ipamorelin

Overview

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the ghrelin receptor (GHS-R1a). Developed in the late 1990s by Novo Nordisk, it is a third-generation Growth Hormone Releasing Peptide (GHRP).

It is widely categorized as the "cleanest" GHRP because it offers the highest selectivity for Growth Hormone (GH) release without the cross-reactivity seen in its predecessors like GHRP-2 or GHRP-6.

Key Characteristics

• Origin: Synthetic pentapeptide developed by Novo Nordisk
• Classification: Third-generation GHRP, Ghrelin receptor agonist
• Selectivity: Highest among GHRPs for pure GH release
• Unique Feature: Does not significantly increase cortisol, prolactin, or cause hunger spikes

Mechanism

Ipamorelin mimics the hormone ghrelin to signal the pituitary gland, but it does so with a specific "safety" profile:

Primary Mechanisms

1. Selective GH Release

It triggers a significant GH pulse by binding to the ghrelin receptor, but unlike GHRP-2 or GHRP-6, it does not significantly increase:

• ACTH (Adrenocorticotropic Hormone)
• Cortisol
• Prolactin levels

This selectivity holds true even at high doses.

2. Preserved Pulsatility

It enhances the body's natural pulsatile GH secretion patterns rather than causing a constant, unphysiological "bleed" of hormone.

3. Somatostatin Inhibition

It acts to suppress somatostatin—the "off switch" for growth hormone—allowing the natural GHRH signal to be more effective.

4. Secondary IGF-1 Rise

Like all GH secretagogues, its use leads to a downstream increase in IGF-1 (Insulin-like Growth Factor-1) produced by the liver, which drives systemic repair and metabolic changes.

Research

Sleep Architecture

2025 clinical observations highlight that Ipamorelin uniquely increases the duration of Slow Wave Sleep (Deep Sleep), which is the primary window for natural physiological repair.

Bone Mineral Density

Recent 2026 data suggests Ipamorelin is highly effective in stimulating osteoblast activity, making it a focus for research into age-related bone density loss.

Gastrointestinal Recovery

Historically studied for post-operative ileus, trials continue to explore its ability to safely restart gut motility without the "hunger spikes" associated with older ghrelin mimetics.

Muscle Preservation

Research focuses on its "anti-catabolic" properties, showing it can preserve lean mass during periods of high stress or caloric restriction without disrupting blood glucose.

Dosing

Research Protocols

Ipamorelin is famous for its "bell-shaped" dose-response curve, meaning more isn't always better.

Administration Notes

The "Nightly Ritual"

• Taking it before bed is preferred to maximize synergy with the body's natural nocturnal GH pulse

The "Fasted" Rule

• Insulin is a direct antagonist to GHRPs
• For maximum effectiveness, must be fasted (no food for 2 hours before or 30-60 minutes after injection)

Reconstitution

• Use bacteriostatic water for reconstitution
• Store reconstituted peptide refrigerated (2-8°C)
• Stable for several weeks when properly stored

Pharmacokinetics

Absorption

• Subcutaneous: Rapid absorption with peak GH release within 30-45 minutes
• Bioavailability is high via subcutaneous route

Distribution

• Acts primarily on pituitary gland
• Effects are systemic through increased GH and IGF-1

Metabolism

• Metabolized by peptidases
• No significant drug interactions identified

Elimination

• Half-life: Approximately 2-3 hours
• GH pulse duration: 2-3 hours post-injection

Synergy & Stacking

Common Combinations

Ipamorelin + CJC-1295 (No DAC)

The most common stack:

• This combination mimics the dual-signal of GHRH + Ghrelin
• Creates a much larger GH pulse than Ipamorelin used alone
• Often called the "GH peptide stack"

Ipamorelin + Tesamorelin

For those targeting specific visceral fat loss while maintaining the recovery benefits of Ipamorelin.

Ipamorelin + BPC-157

For enhanced recovery:

• Ipamorelin provides systemic GH benefits
• BPC-157 provides localized tissue repair

Comparison: Ipamorelin vs Other GHRPs

| Feature | Ipamorelin | GHRP-2 | GHRP-6 | |---------|------------|--------|--------| | Selectivity | Highest (Pure GH) | Moderate | Low | | Hunger Spike | Minimal to Zero | Moderate | Extreme | | Cortisol Rise | Zero | Moderate | Moderate to High | | Prolactin Rise | Zero | Moderate | Moderate to High | | Sleep Quality | Best | Moderate | Moderate |

Safety

Known Side Effects

Ipamorelin has one of the most favorable safety profiles among GHRPs:

Common (generally mild)

• Water retention (mild, much lower than HGH or GHRP-6)
• Headaches (temporary "pressure" headache during first few days)
• Injection site irritation (mild redness or itching)

Monitoring Required

• Insulin sensitivity: While safer than HGH, chronic high-dose use warrants monitoring of fasting blood glucose

Contraindications

Avoid or use with extreme caution if:

• History of cancer or active malignancy
• Pregnant or breastfeeding
• Under 18 years of age
• Diabetic or pre-diabetic (monitor glucose closely)

Monitoring

Recommended Biomarkers

• Serum IGF-1: Primary marker to confirm effectiveness
• Fasting Glucose & HbA1c: Ensure metabolic health during long-term use
• Deep Sleep Duration: Often tracked via wearables to correlate dosing with recovery quality

During Use

• Track sleep quality and recovery
• Monitor body composition changes
• Note any side effects

Regulatory

Current Status

| Region | Status | |--------|--------| | United States | Not FDA-approved; investigational research chemical | | WADA | Strictly Banned (S2 category) | | Compounding | Widely available in clinical wellness settings |

Detection

• Easily detectable in urine and blood for several days post-dose
• Athletes should be aware of detection windows

Clinical Outlook

As of 2025, Ipamorelin remains one of the most widely available peptides in clinical "wellness" settings due to its high safety profile compared to other GH secretagogues.

References